The strong antitumor effect of IR700‐YY146 PIT herein raises the possibility that IR700‐YY146 PIT is a promising therapeutic option for early‐stage cutaneous melanomas, provided that the tumor is CD146‐positive. This evidence concerns the gene MCAM and cutaneous melanoma.